key: cord-0797210-5iaoany0
authors: Aujayeb, Avinash
title: Clarification on Pleural Effusions in COVID-19
date: 2020-06-11
journal: Radiol Cardiothorac Imaging
DOI: 10.1148/ryct.2020200330
sha: b9443fb4b26bcbb8829621a7267a6ad47edecb71
doc_id: 797210
cord_uid: 5iaoany0

nan

I n p r e s s I n p r e s s

The authors declare no conflict of interest. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

We would like to thank the authors for their professional comments [1] on our article [2] , and greatly appreciate their suggestions.

In our study, a total of 20 patients (out of the 120 patients) had pleural effusion (PE), of which twelve belonged to the routine hospitalization group, five to the ICU group, and three to the mortality group.

A total of twelve patients had bilateral pleural effusion. In 16 of the 20 patients, pleural effusion was trace to small, and four had moderate pleural effusion. Of the four patients with moderate pleural effusion, three had history of congestive heart failure (CHF) and one had no underlying disease but very extensive (> 80%) lung parenchymal involvement. One of the patients with moderate pleural effusion underwent diagnostic thoracentesis, which showed serous fluid with no microbial growth. Of the 12 patients with pleural effusion who were admitted to the routine ward, two had diabetes mellitus (DM) and one had CHF. Of the five patients in the ICU group, one had CHF and, one had chronic renal failure and DM. Of the three patients who had died, one had CHF and one had DM. It is worth mentioning that pleural effusion occurs more commonly in diabetic patients, especially in the setting of community-acquired pneumonia [3] .

The reported prevalence of pleural effusion in COVID-19 pneumonia has been variable in recently published investigations [4] . All the 120 patients in our study were inpatients with more pronounced symptoms than outpatients, which can explain the higher prevalence of pleural effusion than other studies. According to the study by Shi et al [5] , the prevalence of pleural effusion varies depending on the stage of the disease, with a reported prevalence of 13% in the third week after symptoms onset.

Pleural effusion may also be predictive of a worse prognosis and can indicate bacterial superinfection in COVID-19 [4] .

In conclusion, it seems that an accurate comment on the prevalence and etiology of pleural effusion in COVID-19 infection should be based on the presence or absence of underlying medical conditions, study setting, disease stage, and concurrent superimposed bacterial pneumonia. Hence, the presence of pleural effusion cannot always be solely attributed to COVID-19 pneumonia.

Tomographic Features and Short-term Prognosis of Coronavirus Disease 2019 (COVID-19) Pneumonia: A Single-Center Study from Kashan Radiol Cardiothorac Imaging 2020 2:2;e200130

Imaging Profile of the COVID-19 Infection: Radiologic Findings and Literature Review Radiol Cardiothorac Imaging 2020 2:1;e200034

Claus R Postmortem Examination of Patients With COVID-19

A review of a pleural service

COVID-19: information for the respiratory community

Clarification on Pleural Effusions in COVID-19

Computed Tomographic Features and Shortterm Prognosis of Coronavirus Disease 2019 (COVID-19) Pneumonia: A Single-Center Study from Kashan, Iran. Radiol Cardiothoracic Imaging

Etiology and outcome of communityacquired pneumonia in patients with diabetes mellitus

Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious Diseases